Pharmaceutical stalwart Adcock Ingram presents a compelling case for investors seeking resilience amidst potential market turbulence. The group boasts a robust track record, with a mere 3% dip in headline earnings per share (HEPS) during the challenging Covid-impacted...
Read about the Clicks interim results that reveal a 13.2% rise in headline earnings per share and significant market achievements. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
